Delivery Order SPE2DR25D3103-SPE2DR26F9R05
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Naloxone HCL 4 mg nasal spray with a firm fixed price ceiling value of $2,998.20 and an ultimate completion date of November 10, 2025. This competitively awarded, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The contract...
- The Defense Logistics Agency awarded a $3,834.55 firm fixed price delivery order to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2-dose units) on December 10, 2025, with an ultimate completion date of December 11, 2025. This non-competitive delivery order will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement under the company's existing contract vehicle with DLA. This delivery order...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Naloxone 4mg nasal spray (2-count units) with a ceiling value of $5,680.80. This competitively awarded, firm fixed-price delivery order was issued on April 24, 2025, with an ultimate completion date of the same day, indicating an expedited fulfillment requirement. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania....
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Naloxone 4mg nasal spray (2-pack units) under a firm fixed-price contract. The order, valued at $19,782.93, is scheduled for completion by July 3, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting the vendor's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 14, 2025, for the supply of Naloxone HCL 4 mg nasal spray (2-count packages) with a contract ceiling value of $3,013.92. This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded procurement. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of December...
- The Defense Logistics Agency awarded a delivery order valued at $1,519.77 to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2-count units) on August 18, 2025, with completion targeted for August 19, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply framework. Performance will be executed from the company's Conshohocken, Pennsylvania location,...
- The Defense Logistics Agency awarded a delivery order valued at $10,266.71 to AmerisourceBergen Drug Corp for the supply of Naloxone HCl 4 mg nasal spray. This contract, which was competitively awarded with no set-aside designation, has a firm fixed price structure and an ultimate completion date of August 18, 2025. The product will be delivered to a location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,301.63 to AmerisourceBergen Drug Corp for the supply of Naloxone HCL 4 mg nasal spray (2-pack units) on July 23, 2025, with completion required by July 24, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. The...
- AmerisourceBergen Drug Corp was awarded a delivery order on September 17, 2025, for the supply of Naloxone Hydrochloride, an opioid antagonist medication, under a firm fixed-price contract valued at $1,101.72. The contract is non-competitive and scheduled for completion by September 18, 2025, with performance at the company's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray on July 24, 2025, with a ceiling value of $1,583.26 and an ultimate completion date of July 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child contract under the company's larger indefinite delivery vehicle with DLA. This delivery order falls...
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F9R05Delivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on December 18, 2025, by the Defense Logistics Agency for the supply of Naloxone HCl 4 mg nasal spray with a ceiling value of $1,384.94. This is a firm fixed price delivery order with an ultimate completion date of December 19, 2025, and represents a competitively awarded contract with no set-aside designation. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 prime vendor vehicle valued through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare operations globally. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen fulfills a wide range of medical supply needs for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive portfolio of federal contract awards demonstrates its capability to deliver both brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This delivery order for naloxone, an opioid antagonist medication, supports the Department of Defense's healthcare supply requirements and reflects the company's role as a primary supplier for emergency medical interventions within the military health system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 12/17/25 |